subscribeSubscribe
Seagen’s former commercial chief joins the board at healthcare agency

Seagen’s former commercial chief joins the board at healthcare agency
Beth Snyder Bulik ENDPTS
22 Mar 2024
Share Share
TUKYSA® Improves Progression-Free Survival in Patients with Breast Cancer

TUKYSA® Improves Progression-Free Survival in Patients with Breast Cancer
BUSINESSWIRE
06 Dec 2023
Share Share
Overall survival data blur Seagen`s Tukysa-ADC path

Overall survival data blur Seagen`s Tukysa-ADC path
Angus Liu FIERCE PHARMA
06 Dec 2023
Share Share
Seagen`s breast cancer drug Tukysa boosts Roche`s ADC

Seagen`s breast cancer drug Tukysa boosts Roche`s ADC
Angus Liu FIERCE PHARMA
17 Aug 2023
Share Share
Seagen says Tukysa combo hits main goal in Phase III breast cancer study

Seagen says Tukysa combo hits main goal in Phase III breast cancer study
BUSINESSWIRE
17 Aug 2023
Share Share
Seagen Announces FDA Accelerated Approval of TUKYSA with Trastuzumab

Seagen Announces FDA Accelerated Approval of TUKYSA with Trastuzumab
BUSINESSWIRE
19 Jan 2023
Share Share
Seagen secures FDA review on Tukysa as Merck buyout talks reportedly stall

Seagen secures FDA review on Tukysa as Merck buyout talks reportedly stall
Nicole DeFeudis ENDPTS
20 Sep 2022
Share Share
Seagen to Highlight Research in Urothelial & Colorectal Cancers at ESMO Congress

Seagen to Highlight Research in Urothelial & Colorectal Cancers at ESMO Congress
BUSINESSWIRE
07 Sep 2022
Share Share
Seagen Announces Results from Pivotal MOUNTAINEER Trial in TUKYSA

Seagen Announces Results from Pivotal MOUNTAINEER Trial in TUKYSA
BUSINESSWIRE
02 Jul 2022
Share Share
Seagen`s Tukysa shows promise in colorectal cancer

Seagen`s Tukysa shows promise in colorectal cancer
K. Dunleavy FIERCEPHARMA
24 May 2022
Share Share